设为首页 加入收藏

TOP

GILENYA 0.5 mg hard capsules Hydrochloride
2015-01-12 19:05:23 来源: 作者: 【 】 浏览:722次 评论:0

For doctors

 

What is it and how is it used?

What Gilenya is
The active substance of Gilenya is fingolimod.

What Gilenya is used for
Gilenya is used in adults to treat relapsing-remitting multiple sclerosis (MS), more specifically in: Patients who have failed to respond despite treatment with beta-interferon (another MS treatment). or
Patients who have rapidly evolving severe MS.

Gilenya does not cure MS, but it helps to reduce the number of relapses and to slow down the progression of physical disabilities due to MS.

What is multiple sclerosis
MSis a long-term condition that affects the central nervous system (CNS), comprised of the brain and spinal cord. In MS inflammation destroys the protective sheath (called myelin) around the nerves in the CNS and stops the nerves from working properly. This is called demyelination.

Relapsing-remitting MS is characterised by repeated attacks (relapses) of nervous system symptoms that reflect inflammation within the CNS. Symptoms vary from patient to patient but typically involve walking difficulties, numbness, vision problems or disturbed balance. Symptoms of a relapse may disappear completely when the relapse is over, but some problems may remain.

How Gilenya works
Gilenya helps to protect against attacks on the CNS by the immune system by reducing the ability of some white blood cells (lymphocytes) to move freely within the body and by stopping them from reaching the brain and spinal cord. This limits nerve damage caused by MS.

What do you have to consider before using it?

Do not take Gilenya

Take special care with Gilenya
Talk to your doctor before taking Gilenya:

Slow heart rate (bradycardia) and irregular heartbeat: At the beginning of treatment, Gilenya causes the heart rate to slow down. As a result, you may feel dizzy or tired, or be consciously aware of your heartbeat, or your blood pressure may drop. If these effects are pronounced, tell your doctor, because you may need treatment right away. Gilenya can also cause an irregular heartbeat, especially after the first dose. Irregular heartbeat usually returns to normal in less than one day. Slow heart rate usually returns to normal within one month.

Your doctor will ask you to stay at the surgery or clinic for 6 hours after taking the first dose of Gilenya so that appropriate measures can be taken in the event of side effects that occur at the start of treatment. The same applies if you are resuming treatment after a break of more than two weeks.

If you have an irregular or abnormal heartbeat or a history of sudden loss of consciousness, your condition may worsen temporarily with Gilenya. If any of this applies to you, your doctor may check your heart before you start treatment with Gilenya.

The same applies if you have a slow heart rate (less than 55 beats per minute), or if you are taking medicines called beta blockers (which slow the heartbeat).

If you have never had chickenpox: If you have never had chickenpox, your doctor may want to check your immunity against the virus that causes it (varicella zoster virus). If you are not protected against the virus, you may need a vaccination before you start treatment with Gilenya. If this is the case, your doctor will delay the start of treatment with Gilenya by one month.

Infections: Gilenya lowers the white blood cell count (particularly the lymphocyte count). White blood cells fight infection. While you are taking Gilenya (and for up to 2 months after you stop taking it), you may get infections more easily. Any infection that you already have may get worse. Infections could be serious and life-threatening. If you think you have an infection, have fever, or feel like you have the flu, call your doctor right away.

Macular oedema: Before you start Gilenya, if you have or have had visual disturbances or other signs of swelling in the central vision area (macula) at the back of the eye, inflammation or infection of the eye (uveitis) or diabetes, your doctor may want you to undergo an eye examination.

Your doctor may want you to undergo an eye examination 3 to 4 months after starting Gilenya treatment.

The macula is a small area of the retina at the back of the eye which enables you to see shapes, colours, and details clearly and sharply. Gilenya may cause swelling in the macula, a condition that is known as macular oedema. The swelling usually happens in the first 4 months of Gilenya treatment.

Your chance of developing macular oedema is higher if you have diabetes or have had an inflammation of the eye called uveitis. In these cases your doctor will want you to undergo regular eye examinations in order to detect macular oedema.

If you have had macular oedema, talk to your doctor before you resume treatment with Gilenya.

Macular oedema can cause some of the same vision symptoms as an MS attack (optic neuritis). Early on, there may not be any symptoms. Be sure to tell your doctor about any changes in your vision. Your doctor may want you to undergo an eye examination, especially if:

Liver function tests: If you have severe liver problems, you should not take Gilenya.Gilenya may cause abnormal results of liver function tests. You will probably not notice any symptoms but if you notice yellowing of your skin or the whites of your eyes, abnormal darkening of the urine or unexplained nausea and vomiting, tell your doctor straight away.

If you get any of these symptoms after starting Gilenya, tell your doctor straight away.

During the first six months of treatment your doctor will request blood tests to monitor your liver function. If your test results indicate a problem with your liver you may have to interrupt treatment with Gilenya.

High blood pressure
As Gilenya causes a slight elevation of blood pressure, your doctor may want to check your blood pressure regularly.

Lung problems
Gilenya has a slight effect on the lung function. Patients with severe lung problems or with smoker-s cough may have a higher chance of developing side effects.

Blood count
The desired effect of Gilenya treatment is to reduce the amount of white blood cells in your blood. This will usually go back to normal within 2 months of stopping treatment. If you need to have any blood tests, tell the doctor that you are taking Gilenya. Otherwise, it may not be possible for the doctor to understand the results of the test, and for certain types of blood test your doctor may need to take more blood than usual.

Before you start Gilenya, your doctor will confirm whether you have enough white blood cells in your blood and may want to repeat a check regularly. In case you do not have enough white blood cells, you may have to interrupt treatment with Gilenya.

Elderly
Experience with Gilenya in elderly patients (over 65 years) is limited. Talk to your doctor if you have any concerns.

Use in children
Gilenya is not intended to be used in children and adolescents below 18 years old as it has not been studied in MS patients below 18 years old.

Taking other medicines
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. Tell your doctor if you are taking any of the following medicines:
- Medicines that suppress or modulate the immune system, including other medicines used to treat MS, such as beta interferon, glatiramer acetate, natalizumab or mitoxantrone. You must not use Gilenya together with such medicines as this could intensify the effect on the immune system (see also „Do not take Gilenya-).
- Vaccines. During and for up to 2 months after treatment with Gilenya, you should not be given certain types of vaccine (live attenuated vaccines) as they could trigger the infection that they were supposed to prevent. Other vaccines may not work as well as usual if given during this period.
- Medicines that slow the heartbeat (for example beta blockers, such as atenolol). Use of Gilenya together with such medicines could intensify the effect on heartbeat in the first days after starting Gilenya.
- Medicines for irregular heartbeat, such as quinidine, disopyramide, amiodarone or sotalol. Your doctor may decide not to prescribe Gilenya if you are taking such a medicine because it could intensify the effect on irregular heartbeat.
- Other medicines: protease inhibitors, anti-infectives such as ketoconazole, azole antifungals, clarithromycin or telithromycin.

Pregnancy and breast-feeding
Before you start treatment with Gilenya your doctor may ask you to do a pregnancy test in order to ensure that you are not pregnant. You should avoid becoming pregnant while taking Gilenya or in the two months after you stop taking it because there is a risk of harm to the baby. Talk with your doctor about reliable methods of birth control that you should use during treatment and for 2 months after you stop treatment.

If you do become pregnant while taking Gilenya, stop taking the medicine and tell your doctor straight away. You and your doctor will decide what is best for you and your baby.

You should not breast-feed while you are taking Gilenya. Gilenya can pass into breast milk and there is a risk of serious side effects for the baby.

Ask your doctor or pharmacist for advice before taking any medicine.

Driving and using machines
Your doctor will tell you whether your illness allows you to drive vehicles and use machines safely. Gilenya is not expected to have an influence on your ability to drive and use machines.

However, at initiation of treatment you will have to stay at the doctor-s surgery or clinic for 6 hours after taking the first dose of Gilenya. Your ability to drive and use machines may be impaired during and potentially after this time period.

How is it used?

Treatment with Gilenya will be overseen by a doctor who is experienced in the treatment of multiple sclerosis.

Always take Gilenya exactly as your doctor has told you. You should check with your doctor if you are not sure.

The dose is one capsule per day. Take Gilenya once a day with a glass of water. Gilenya can be taken with or without food.

Taking Gilenya at the same time each day will help you remember when to take your medicine.

Do not exceed the recommended dose.

Your doctor may switch you directly from beta interferon to Gilenya if there are no signs of abnormalities caused by your previous treatment. Your doctor may have to do a blood test in order to exclude such abnormalities. After stopping natalizumab you may have to wait for 2-3 months before starting treatment with Gilenya.

If you have questions about how long to take Gilenya, talk to your doctor or your pharmacist.

If you take more Gilenya than you should
If you have taken too much Gilenya, call your doctor straight away.

If you forget to take Gilenya
If you forget to take a dose, take the next dose as planned. Do not take a double dose to make up for a forgotten dose.

If you stop taking Gilenya
Do not stop taking Gilenya or change your dose without talking to your doctor first.

Gilenya will stay in your body for up to 2 months after you stop taking it. Your white blood cell count (lymphocyte count) may also remain low during this time and the side effects described in this leaflet may still occur. After stopping Gilenya you may have to wait for 6-8 weeks before starting a new MS treatment.

If you have to restart Gilenya more than 2 weeks after you stop taking it, the effect on heart rate normally seen when treatment is first started may re-occur. Talk to your doctor to check if you need to take the first capsule in the doctor-s surgery or clinic.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

What are possible side effects?

Like all medicines, Gilenya can cause side effects, although not everybody gets them.

Side effects may occur with certain frequencies, which are defined as follows:

Very common affects more than 1 user in 10 Common affects 1 to 10 users in 100 Uncommon affects 1 to 10 users in 1,000 Rare affects 1 to 10 users in 10,000 Very rare affects less than 1 user in 10,000 Not known frequency cannot be estimated from the available data.

Some side effects could be or could become serious
Common:

Uncommon:

Other side effects
Very common

Common

Uncommon

Rare

If any of these affects you severely, tell your doctor

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

How should it be stored?

Keep out of the reach and sight of children.
Do not use Gilenya after the expiry date which is stated on the carton and blister foil after “EXP”. The expiry date refers to the last day of the month.
Do not store above 30ºC.
Store in the original package in order to protect from moisture.
Do not use any pack that is damaged or shows signs of tampering.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

↑ back to table of contents ↑

For doctors

What is it?

Gilenya is a medicine that contains the active substance fingolimod. It is available as capsules (0.5 mg).

What is it used for?

Gilenya is used to treat adults with highly active multiple sclerosis (MS). MS is a disease of the nerves, in which inflammation destroys the protective sheath surrounding the nerve cells. Gilenya is used in the type of MS known as ‘relapsing-remitting’, when the patient has attacks (relapses) in between periods with decreased symptoms (remissions). It is used when the disease has failed to respond to a beta-interferon (another type of medicine used in MS), or is severe and getting worse rapidly.

The medicine can only be obtained with a prescription.

How is it used?

Treatment with Gilenya should be started and supervised by a physician experienced in MS. The recommended dose is one capsule taken once a day by mouth.

How does it work?

In MS, the body’s immune system malfunctions and attacks parts of the central nervous system (the brain and spinal cord). The active substance in Gilenya, fingolimod, reduces the ability of T cells (a type of white blood cell involved in the immune system) to move from the lymph nodes towards the brain and spinal cord thus limiting the damage they cause in MS. It does this by blocking the action of a receptor on the T cells called the sphingosine-1-phosphate receptor, which is involved in regulating the movement of these cells in the body.

How has it been studied?

The effects of Gilenya were first tested in experimental models before being studied in humans.

Gilenya at two doses (0.5 mg and 1.25 mg) was investigated in two main studies in MS patients. In one study, Gilenya was compared with placebo over two years in 1,272 patients with relapsing-remitting MS. In the second study Gilenya was compared with beta-interferon over one year in 1,292 patients. The main measure of effectiveness in both studies was based on the number of relapses the patients experienced each year.

What benefits has it shown during the studies?

Gilenya was shown to be more effective than placebo and beta-interferon in reducing the number of relapses. The lower dose of Gilenya was shown to be as effective as the higher dose. In the first study, the number of relapses per year among patients treated with Gilenya was around half the number seen in patients given placebo. In the second study, the number of relapses in patients receiving Gilenya was also around half the number seen in patients given beta-interferon.

What is the risk associated?

The most common side effects with Gilenya (seen in more than 1 patient in 10) are flu infections, headache, cough, diarrhoea, back pain and raised liver enzyme levels. For the full list of all side effects reported with Gilenya, see the package leaflet.

Gilenya should not be used in people who may be hypersensitive (allergic) to fingolimod or any of the other ingredients. Gilenya must not be used in patients at risk of infections due to a weakened immune system, patients with a severe infection or a long-term infection such as hepatitis, cancer (except a type of skin cancer called ‘basal cell carcinoma’) or severe liver problems. Women should avoid becoming pregnant while taking Gilenya and for two months after treatment has stopped.

Why has it been approved?

The CHMP concluded that the effectiveness of Gilenya had been shown and noted that it had the benefit of being taken by mouth. However, because of its safety profile, the Committee concluded that Gilenya should only be used in patients who have a real need for the medicine either because they have failed to respond to a beta-interferon or because their disease is severe and getting worse rapidly. The Committee decided that Gilenya’s benefits are greater than its risks and recommended that it be given marketing authorisation.

How has it been studied?

The company that makes Gilenya must ensure that all doctors who intend to prescribe Gilenya receive an information pack containing important safety information including a checklist of the risks with Gilenya and the tests and monitoring that should be carried out in patients. The pack will also include information on the registry the company will set up to collect data on babies born to women treated with Gilenya, as well as a patient reminder card with key safety information for patients.

Further information

The European Commission granted a marketing authorisation valid throughout the European Union for Gilenya to Novartis Europharm Ltd on 17 March 2011. The marketing authorisation is valid for five years, after which it can be renewed. europa.eu/Find medicine/Human medicines/European Public Assessment Reports. For more information about treatment with Gilenya, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

This summary was last updated in 02-2011.

↑ back to table of contents ↑
 

Name

 

GILENYA 0.5 mg hard capsules

 

Composition

 

Each capsule contains 0.5 mg fingolimod (as hydrochloride).

For a full list of excipients, see section 6.1.

 

Pharmaceutical Form

 

Hard capsule

Capsule of 16 mm with bright yellow opaque cap and white opaque body; imprint with black ink, “FTY0.5 mg” on cap and two radial bands imprinted on the body with yellow ink.

 

Are you an Healthcare Professional? Access professional drug leaflets on Diagnosia.com!

 

以下是“全球医药”详细资料
Tags: 责任编辑:admin
】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇azithromycin (Zedbac) 阿奇霉素.. 下一篇Ellaone 30 mg compresse

相关栏目

最新文章

图片主题

热门文章

推荐文章

相关文章

广告位